The Allosteric Hit Nobody Saw Coming: Terry Kenakin

The Assay That Has To Survive Lot Release - DiscoverX

The Part of Drug Discovery Where Most Compounds Die

Can One Molecule Be an Agonist and an Antagonist?

Keeping the Muscle When the Fat Comes Off

Finding Chemical Matter for a Receptor With No Known Function

Can GPCR Variants Predict Psychiatric Drug Failure? - Alexander S. Hauser

He Turned Down Med School for a GPCR - Antony Boucard

What If Your Assay Has Been Lying to You? - Kathryn E Livingston

Can You Drug a Receptor Nobody Understands? — Gunnar Schulte

GPCR Signaling Isn't Just at the Plasma Membrane

He Left the Bench to Unlock 800 Receptors - Brian Bender

The Receptor Keeps Signaling After It's Internalized: Endosomal PTH1R | Jakob Höppner

He Bet His Career on a Database - David E. Gloriam

Half the Room Wanted to Burn Him - Michel Bouvier

When the Curve Fits, You Never Forget - Samuel Hoare

Measuring Amylin, Not Calcitonin - Agrawal

Why Your Compound Fails In Vivo - Sam Hoare

Can Intuition Drive Drug Discovery? - Brian Arey part 2

Why the Dose Response Was Bell-Shaped - Brian Arey

He Co-Founded a Company. Never Wanted To. - Chris Tate

They Said Receptors Were Imaginary - Dr Robert J Lefkowitz

Subcellular Regulation of PTH1R Signaling - Dr. Jakob Höppner

Bias Isn't Optional. It's Already There - @TerryPharmacologyCorner & Eurofins DiscoverX

The Time Point Changes Everything - Kevin Pfleger

The GPCR Antibody Problem Nobody Fixed - GeneTex - Alexander Ball & Chia Yi Lin

She Nodded Yes. She Had No Idea. - Elva Zhao

A Receptor That Shouldn't Exist Yet / Beatriz Redondo

Making Drugs You Can Actually See - Eleonora Comeo

Why Chimeric GPCRs Fail When They Shouldn't - Charlotte Crauwels

Why GPCR Medicinal Chemistry Still Runs on Serendipity - Chris Dockendorf

SAR Meets GPCR Structure - Dr. Ken Jacobson & Matteo Pavan

Why Location Beats Activation — Sudarshan Rajagopal

Why GPCR Drugs Stall Before The Clinic — Andrew Tobin

Why Potency Misses the Real Drug Story — Sam Hoare

Can a Beta-2 Agonist Avoid Desensitization?/ Tore Bengtsson

Most GPCR Teams Wait Too Long For Cryo-EM — Giovanna Scapin

When Poly-pharmacology Stopped Being a Dirty Word

The GPCR Nobody Can Drug - Joseph Kim

Bryan Roth on GPCR Molecular Glues and Biased Modulation at the Transducer Interface

Tracing Ligand Bias Through GPCR Allosteric Networks

Why Imaging the GLP-1 Receptor in Native Tissue Was Harder Than We Thought

Studying GPCR Pharmacology in Patient-Derived iPSC Models - Terry Hebert

Adenosine Receptor Ligand Design: Ken Jacobson on A3 Agonists & GPCR Pharmacology

GLP-1 Receptor Biology: From Incretin Signaling to Metabolic Therapeutics

Unconventional Ligands in GPCR Drug Discovery: Prodrugs, Biologics, and Beyond | #GPCRMasterclass

Exploitable GPCR Ligand Behaviors: From Dimerization to Location Bias | #GPCRMasterclass

Drug Diffusion & Tissue Barrier-GPCR Therapeutics: Practical Impact on Drug Design #GPCRMasterclass

Blood, Mating & GPCRs: Why Mosquitoes Hunt You | Laura Duvall 182

GPCR Ligand Kinetics: Real-World Impact for Drug Discovery | #GPCRMasterclass

Quantifying Efficacy and Pathway Bias in GPCR Pharmacology with Dr. Terry Kenakin | #GPCRMasterclass

Allosteric Modulation in GPCRs: Mechanistic Differences and Therapeutic Impact | #GPCRMastreclass

Measuring GPCR Antagonist Affinity: Models, Pitfalls, and Practical Solutions | #GPCRMasterclass

Signaling Bias in GPCRs: Practical Tools for Interpretation and Drug Discovery | #GPCRMasterclass

Advanced Approaches to Quantifying Ligand Binding and Affinity in GPCR Systems | #GPCRMasterclass

GPCR Drug Discovery: Strategies from Target Selection to Lead Optimization | #GPCRMasterclass

Advanced GPCR Data Analysis: Operational Model and Biased Agonism | #GPCRMasterclass

Allosteric Modulation and GPCR Flexibility: Rethinking Drug Discovery | #GPCRMasterclass

Advanced Allosteric Modulation and Kinetics in GPCR Drug Discovery | #GPCRMasterclass

How Lipid Rafts Influence GPCR Signaling | Keyvan Sedaghat 181